William A. Carlezon

William A. Carlezon

Auto-generated profile, based on publicly available information

William A. Carlezon

Department of Psychiatry, Harvard Medical School, Boston, MA, USA, 02115

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2009 in Neuropharmacology
Verified
Journal Article
Closed access
WCWilliam A. Carlezon
William A. Carlezon
MTMark Thomas
Mark Thomas

1 February 2010 in Brain Research
Verified
Journal Article
Closed access
AKAllison T. Knoll
Allison T. Knoll
WCWilliam A. Carlezon
William A. Carlezon

15 November 2007 in Nature Protocols
Verified
Journal Article
Closed access
WCWilliam A Carlezon
William A Carlezon
ECElena H Chartoff
Elena H Chartoff

1 January 2006 in The Journal of Pharmacology and Experimental Therapeutics
Verified
Journal Article
Closed access
PDF file
WCWilliam A. Carlezon
William A. Carlezon
CBCécile Béguin
Cécile Béguin
JDJennifer A. DiNieri
Jennifer A. DiNieri
MBMichael Baumann
Michael Baumann
MRMichele R. Richards
Michele R. Richards
BCBruce M. Cohen
Bruce M. Cohen
Endogenous opioids seem to play a critical role in the regulation of mood states. For example, there is accumulating evidence that stimulation of κ-opioid receptors, upon which the endogenous opioid dynorphin acts, can produce depressive-like behaviors in laboratory animals. Here we examined whether systemic administration of salvinorin A (SalvA), a potent and highly selective κ-opioid agonist, would produce depressive-like effects in the forced swim test (FST) and intracranial self-stimulation (ICSS) test, which are behavioral models often used to study depression in rats. We extracted, isolated, and purified SalvA from Salvia divinorum plant leaves and examined its effects on behavior in the FST and ICSS test across a range of doses (0.125–2.0 mg/kg) after systemic (intraperitoneal) administration. SalvA dose dependently increased immobility in the FST, an effect opposite to that of standard antidepressant drugs. Doses of SalvA that produced these effects in the FST did not affect locomotor activity in an open field. Furthermore, SalvA dose dependently elevated ICSS thresholds, an effect similar to that produced by treatments that cause depressive symptoms in humans. At a dose that caused the depressive-like effects in both the FST and ICSS assays, SalvA decreased extracellular concentrations of dopamine (DA) within the nucleus accumbens (NAc), a critical component of brain reward circuitry, without affecting extracellular concentrations of serotonin (5-HT). These data provide additional support for the hypothesis that stimulation of brain κ-opioid receptors triggers depressive-like signs in rats and raise the possibility that decreases in extracellular concentrations of DA within the NAc contribute to these effects.

30 June 2017 in Dialogues in clinical neuroscience
Verified
Journal Article
Open access
KLKimberly R. Lezak
Kimberly R. Lezak
GMGalen Missig
Galen Missig
WJWilliam A. Carlezon Jr
William A. Carlezon Jr
Stress is a precipitating factor for anxiety-related disorders, which are among the leading forms of psychiatric illness and impairment in the modern world. Rodent-based behavioral tests and models are widely used to understand the mechanisms by which stress triggers anxiety-related behaviors and to identify new treatments for anxiety-related disorders. Although substantial progress has been made and many of the key neural circuits and molecular pathways mediating stress responsiveness have been characterized, these advances have thus far failed to translate into fundamentally new treatments that are safer and more efficacious in humans. The purpose of this article is to describe methods that have been historically used for this type of research and to highlight new approaches that align with recent conceptualizations of disease symptomatology and that may ultimately prove to be more fruitful in facilitating the development of improved therapeutics.

1 October 2014 in Biological Psychiatry
Verified
Journal Article
Closed access
RDRachel J. Donahue
Rachel J. Donahue
JMJohn W. Muschamp
John W. Muschamp
SRScott J. Russo
Scott J. Russo
ENEric J. Nestler
Eric J. Nestler
WCWilliam A. Carlezon
William A. Carlezon